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ABSTRACT
Background: Cyclin A overexpression is found in a variety of human tumors and
correlates with unfavorable outcome. We analyzed immunohistochemical expression of
cyclin A in Wilms tumor (WT) in relation to clinicopathological characteristics,
preoperative chemotherapy (PrOpChTh), and overall survival (OS).
Methods: This retrospective study involved 43 patients who underwent
nephrectomy from January 1996 to October 2010. Tumor stage and histological
subtype were determined by revised Societé International d’Oncologie Pediatrique
protocol, based on histological components/alterations caused by PrOpChTh,
within the prognostic group of low, intermediate and high risk, and with criteria for
anaplasia. The regressive/necrotic changes in total tumor mass of primary
tumor and the proportion of epithelial, blastemal, and stromal components in the
remaining viable tumor tissue were also determined. Cyclin A expression was
evaluated by immunohistochemistry using a polyclonal rabbit, antihuman
antibody (H-432).
Results: Cyclin A overexpression was found in 34.3% of WTs, with higher frequency
in tumors with epithelial (31.3%) and blastemal (37.1%) components than
those with stromal component (17.7%). Regarding histological type, cyclin A
overexpression was found most often in focal anaplasia (100%), stromal (60%), and
diffuse anaplastic (66.7) WTs. The overexpression was also more frequent in
stages 3 and 4 (77.8% and 66.7%, respectively) compared to tumors in stages 1 and 2
(13.3% and 12.5%, respectively; p = 0.004) in all components, as well as in blastemal
component in stages 3 and 4 (77.8% and 66.7%, respectively) vs. stages 1 and 2
(13.3% and 25%, respectively, p = 0.009). Cyclin A overexpression in all components
was 66.7% in WTs with metastasis and 31.3% in WTs without metastasis
(p = 0.265, Fisher test). Log-rank testing revealed differences of OS regarding stage
(p = 0.000), prognostic groups (p = 0.001), and cyclin A expression in blastemal
component (p = 0.025). After univariate analysis, tumor stage (p = 0.001), prognostic
group (p = 0.004), and cyclin A expression in blastemal component (p = 0.042)
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were signiﬁcant prognostic factors for OS; however, after multivariate analysis, none
of these factors were conﬁrmed as independent predictors of survival.
Discussion: This study showed that cyclin A overexpression might be associated with
the development and progression of WT with anaplasia. Also, cyclin A
overexpression was more often observed in advanced stages (3 and 4) of WT, in the
group of high-risk WTs, and in focal and diffuse anaplasia WTs. There was no
relation of cyclin A overexpression and metastatic ability of WT. Although this study
has not conﬁrmed the prognostic value of cyclin A overexpression, its association
with unfavorable prognosis should be further evaluated.
Subjects Nephrology, Oncology, Pathology, Pediatrics, Urology
Keywords Wilms tumor, Immunohistochemistry, Survival, Cyclin A, Retrospective study
INTRODUCTION
The cell cycle is regulated by the three main groups of proteins: cyclins, cyclin-dependent
kinases (CDKs), and cyclin-dependent kinase inhibitors (CKIs). The CDKs are a family of
serine/threonine kinases involved in transitions between phases of cell cycle and they
require association with cyclins for their activity (Lim & Kaldis, 2013). Cyclin A is
associated with CDK1 and CDK2 and has functions in both S phase and mitosis
(Yam, Fung & Poon, 2002). It is expressed from the late G1 phase till early mitosis, reaches
a maximum in late S phase and G2 phase (Krabbe, Margulis & Lotan, 2016), when,
associating with CDK1, it triggers the initiation of chromosome condensation and possibly
nuclear envelope breakdown (Gong et al., 2007). Abnormalities in cell-cycle control
underlie the aberrant cell proliferation that characterizes cancer (Williams & Stoeber,
2012), thus immunohistochemical (IHC) assessment of cell-cycle proteins has a diagnostic
utility in histopathology (Thway et al., 2012). Association between cyclin A overexpression
and poor prognosis was conﬁrmed in a variety of human tumors (Handa et al., 1999;
Ito et al., 2002; Chen et al., 2003; Saarilahti et al., 2003). In medulloblastoma, the cyclin A
index >40% was associated with poorer survival (Moschovi et al., 2011). In contrast,
there are few studies reporting cyclin A overexpression in normal colon mucosa
(Wang et al., 1996) and in ovarian carcinomas with a more prolonged survival
(Davidson et al., 2001).
Wilms tumor (WT) is one of the most common genitourinary malignant solid tumors
in childhood (Radojevic-Skodric et al., 2012). It comprises 90% of pediatric renal tumors
(Brok et al., 2016) with an annual incidence of 1 in 10,000 children worldwide
(Breslow et al., 1993). The highest incidence of WT occurs in ﬁrst 4 years of life, and it’s
relatively uncommon in children older than 6 years (Martignoni et al., 2007). The WT is
genetically heterogeneous disease in which somatic changes include mutations in
Wilms tumor 1 (WT1) (10–20%), catenin beta 1 (CTNNB1) (15%), Wilms tumor gene on
the X chromosome protein (WTX) (15–20%), tumor protein P53 (TP53) (70% of anaplastic
tumors) (Park et al., 1993; Koesters et al., 1999; Rivera et al., 2007; Maschietto et al.,
2014), and imprinting control region that controls expression of insulin-like growth factor 2
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gene and adjacent H19 (37% of tumors) (Scott et al., 2012). Normal WT1 expression is
essential for blastemal cells differentiation into the mature epithelial component of kidney
parenchyma, and disruption of this expression may result in the development of cells
with the potential for tumor formation (Grubb et al., 1994). Latest research has shown that
gain of 1q is associated with poorer survival in WT patients in addition to histologic
response to preoperative chemotherapy (PrOpChTh) and tumor stage (Chagtai et al.,
2016). Genomic gain of the N-Myc proto-oncogene protein (MYCN) is associated with poor
prognosis in several childhood cancers. Some results suggest a signiﬁcant role for MYCN
dysregulation in the molecular biology of WT and conclude that MYCN gain is
prognostically signiﬁcant for this type of disease (Williams et al., 2015). However, the only
genomic biomarker associated with poor outcome is simultaneous loss of heterozygosity
of chromosomes 1p and 16q, and it was validated in WT patients with surgery as
the ﬁrst therapeutic intervention (Grundy et al., 2005; Gratias et al., 2016). Some studies
regarding IHC examination of cell cycle regulators in WT have been published so far.
Different authors have shown that antigen Ki67 proliferation index was signiﬁcantly
correlated with tumor stage in WT patients (Krishna et al., 2016) but also that blastemal
type of WT shows more pronounced expression of CKI 2A (p16) and cyclin E
(Radojevic-Skodric et al., 2007; Basta-Jovanovic et al., 2008). The higher values of cyclin E
were also observed in WT with metastases and recurrences (Taran et al., 2011).
Expression of tumor markers WT1, transforming growth factor alpha, vascular endothelial
growth factor, E3 ubiquitin-protein ligase (MIB1), and CKI 1B (p27Kip1) correlates
with clinical progression of tumor (Ghanem et al., 2013), while Ki67 is a relevant marker
for assessing the proliferative activity, but it may not be a good clinical prognostic marker
(Juric et al., 2010).
The aim of this study was to analyze cyclin A IHC expression in WT metastases and
primary tumors, as well as its relation to clinicopathological characteristics and overall
survival (OS). We hypothesized that cyclin A overexpression may be associated with
histopathological ﬁnding of WT and progression.
MATERIALS AND METHODS
Study design and patients
This retrospective study was conducted on tumor specimens and clinical data of patients
with WT who underwent nephrectomy between January 1996 and October 2010.
All specimens were obtained from the archives of Institute of Pathology, School of
Medicine, University of Belgrade, Serbia (where the study was performed) and Mother and
Child Health Care Institute of Serbia “Dr. Vukan Čupic,” Belgrade, Serbia. Of the available
59 samples, fourteen cases were excluded due to inadequate sampling or incomplete
clinical data and two were excluded as bilateral tumors thus, the study was limited to
43 patients.
For each patient included in the study, available clinical–morphological data were
collected by reviewing the patients’ medical histories. The data collected included sex, age
(months), tumor stage, histological type, and prognostic group (Table 1). The mean age of
patients was 52.4 months (range 7–132 months) and there were 28 (65.1%) females
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Table 1 Clinical data, morphological features and cyclin A expression in primary Wilms tumors and metastasis.
Number Age
(months)
Sex Preoperative
therapy
Tumor
size (cm)
Stage Histological
type
Prognostic
group
Cyclin A expression in tumor components
E B S T
1 23 F Yes 7 I Mixed IR + + + +
2 14 F Yes 8 II Stromal IR ++ ++ + ++
3* 18 F Yes 7 IV Stromal IR + ++ ++ ++
4 24 F Yes 7 I Stromal IR + + + +
5 48 F Yes 6 I Mixed IR - - - -
6 36 F Yes 6 I Blastemal HR - + + +
7 60 F Yes 6 I Blastemal HR + + + +
8 24 M Yes 8 III Anaplastic IR + + + +
9 84 M Yes 8 III Anaplastic HR ++ ++ ++ ++
10 132 M Yes 12 I Blastemal HR - - - -
11 36 F Yes 7 II Blastemal HR + + + +
12 84 M Yes 13 I Blastemal HR + + + +
13 24 F Yes 10 I Epithelial IR + + + +
14 12 F Yes 10 I Epithelial IR ++ + / +
15 96 F Yes 16 III Stromal IR - ++ ++ ++
16 132 F Yes 19 III Anaplastic HR ++ ++ + ++
17 24 F Yes 6 I Stromal IR + + + +
18 57 M Yes 8 II Blastemal HR + ++ + +
19 79 M Yes 5 II Mixed IR + + + +
20 132 F Yes 4 III Regressive IR - - - -
21* 36 F Yes 3 IV Regressive IR ++ + + +
22 24 F Yes 6 II Regressive IR + + ++ +
23 36 F Yes 12 I Mixed IR ++ ++ ++ ++
24 60 M Yes 9 II Regressive IR + + + +
25 24 M Yes 5 III Mixed IR / ++ + ++
26 132 F Yes 8 III Anaplasia IR ++ ++ + ++
27 36 F Yes 12 I Mixed IR / + + +
28 108 F Yes 5 II Regressive IR + - - +
29 72 F Yes 7 I Mixed IR + + + +
30* 60 F Yes 10 IV Blastemal HR / ++ + ++
31 24 F Yes 14 III Mixed IR ++ ++ + ++
32 48 F Yes 9 II Regressive IR - - - -
33 24 M Yes 10 III Regressive IR ++ ++ + ++
34 60 M Yes 9 I Anaplasia HR ++ ++ + ++
35 24 M Yes 7 I Mixed IR + + + +
36 7 M No 7 I Blastemal IR + + + +
37 43 F No 9 I Blastemal IR - + - +
38 55 M No 8 I Anaplastic HR ++ ++ + ++
39* 25 F No 7 IV Blastemal IR ++ ++ ++ ++
40 64 F No 3 I Blastemal IR ++ + + +
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and 15 (34.9%) males. The histological diagnoses and classiﬁcation were performed in
accordance with the revised Societé International d’Oncologie Pediatrique (SIOP)
Working Classiﬁcation (Vujanic et al., 2002) criteria for histological subtypes (according to
Section A) and strict adherence to the criteria for anaplasia (Vujanic et al., 1999). Based on
the histological material, WTs were classiﬁed into following risk groups: (a) low risk
(cystic partially differentiated WT), (b) intermediate risk (IR; regressive, epithelial,
stromal, or mixed), and (c) high risk (blastemal or diffuse anaplasia) (Vujanic et al., 2002).
Examination of prognostic signiﬁcance of histologic components of WT characterized by a
different degree of aggressiveness, but also different sensitivity to chemotherapy,
provides a more precise classiﬁcation of tumor subtypes within a group of medium risk
and hence the adaptation of therapeutic protocols.
A total of 35 (81.4%) patients were treated according to SIOP protocols that include
PrOpChTh for all patients older than 6 months, surgical operation, postoperative
chemotherapy, and in some cases radiation therapy, as well as other medical standards and
procedures in diagnosing and treating diseases (SIOP 9, SIOP 6, and some according
to 93-01, depending on the period when the diagnosis was established). For each primary
tumor, the percentage of regressive/necrotic changes in the total tumor mass was
determined by a semiquantitative method, based on the macroscopic and microscopic
examination. In the remaining viable tumor tissue, the proportion of epithelial, blastemal,
and stromal components was determined microscopically. Seven (20%) cases were
predominantly blastemal histological type, nine (25.7%) mixed, seven (20%) regressive,
ﬁve (14.3%) stromal, and two (5.7%) predominantly epithelial. Among anaplastic tumors,
three (8.6%) were diffusely anaplastic and two (5.7%) showed focal anaplasia. The revised
SIOP staging criteria (Vujanic et al., 2002) was also used to determine tumor stage.
Stage 1 was diagnosed in 15 (42.8%) WT cases, stage 2 in eight (22.8%), stage 3 in nine
(25.7%), and stage 4 in three (8.6%) cases. According to the prognostic group, 25 (71.4%)
cases were classiﬁed as intermediate (IR) group and 10 (28.6%) cases as high-risk group (HR).
Table 1 (continued).
Number Age
(months)
Sex Preoperative
therapy
Tumor
size (cm)
Stage Histological
type
Prognostic
group
Cyclin A expression in tumor components
E B S T
41 16 F No 5 I Mixed IR + ++ + +
42 79 M No 9 I Blastemal IR ++ ++ +++ ++
43 55 M No 16 I Anaplastic HR / + + +
m3 +++ ++ ++ ++
m21 +++ / +++ ++
m30/1 ++ / ++ ++
m30/2 ++ / ++ ++
m39 ++ ++ ++ ++
Notes:
M, male; F, female; IR, intermediate risk; HR, high risk; E, epithelial component; B, blastemal component; S, stromal component; T, all components; -, no staining;
+, staining in less than 10% of cells; ++, staining in 10–50% of cells; +++, staining in more than 50% of cells; /, absence of epithelial, blastemal, or stromal component;
m, metastasis.
* Primary tumor with pulmonary metastasis.
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Eight patients (18.6%) were not treated with PrOpChTh and they were analyzed
separately. These cases were classiﬁed according to the Children’s Oncology Group criteria
(blastemal type–IR, and not the high risk as it would be in SIOP). Five cases (62.5%)
were predominantly blastemal histological type, 2 diffusely anaplastic (25%) and 1 (12.5%)
was mixed histological type.
The follow-up period was 5 years and the OS time was deﬁned as a period between date
of surgery and date of death. Patients still alive at the end of the study were censored.
Since according to the State Laws and Legislation patients are not required to receive
therapy or to be followed up in the same clinic where they were diagnosed and operated,
the event free survival could not be analyzed due to insufﬁcient number of subjects to be
included in the analysis.
The study was conducted in accordance with the ethical standards of the 1964 Helsinki
Declaration and applicable national regulations. The ethical approval was received
from Ethics Committee of School of Medicine, University of Belgrade, (1600/I-38). For this
type of study formal consent is not required.
Methods
For each tumor, at least two parafﬁn-embedded tissue sections, representative of the global
histology, were selected for IHC analysis of cyclin A. Tissue samples from formalin-ﬁxed
parafﬁn blocks and polyclonal rabbit antihuman antibody (H-432; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) were used. Deparafﬁnized samples were treated
15 min with hydrogen peroxide solution (3%) to stop peroxidase activity. Thereafter,
samples immersed in 10 mM citrate buffer (pH 6.0) were treated in a microwave oven
(20 min, 620 W) for antigen retrieval. Nonspeciﬁc staining was prevented with blocking
peptide (DAKO, Glostrup, Denmark) the primary antibody for cyclin A (diluted 1:200)
was applied and left overnight at 4 C. Detection was done with streptavidin-biotin
technique (Dako REALTM Detection Systems LSABTM+; DAKO, Glostrup, Denmark).
Finally, chromogen (diaminobenzidine) was applied for IHC development and Mayer’s
hematoxylin for the counterstaining. IHC stained normal lymph node tissue was used as a
positive control, whereas negative control was based on the omission of primary antibody.
Strong nuclear staining was considered positive for cyclin A1. The IHC expression of
cyclin A was scored with semiquantitative technique (Table 1) as previously described
(Todorovic et al., 2014). In normal kidney parenchyma adjacent to the tumor, focal
expression of cyclin A was found in epithelial cells of distal convoluted tubules
(Figs. 1A–1D) while the expression was absent in glomerular cells.
Consequently, moderate and diffuse expression in WT was considered as cyclin A
overexpression. For statistical analyses, cases with no or focal expression and those with
moderate or diffuse expression were grouped together, respectively.
Statistical analysis
Statistical analyses were performed at IC Faculty of Mechanical Engineering, Belgrade,
Serbia, with SPSS 23.0 for Windows (SPSS Inc., Chicago, IL, USA) and GraphPad
Prism 4. Normality of distribution was tested with Shapiro–Wilks test. For testing the
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differences between parameters the Pearson w2 test, Fisher exact test and t-test were used.
The OS was calculated by Kaplan–Meier method and groups were compared using Log-rank
statistics. Univariate and multivariate Cox regression were used to analyze the independent
factors related to OS. The p < 0.05 was considered signiﬁcant.
RESULTS
Cyclin A expression in all components of WT
The overexpression of cyclin A (Table 2) was almost equal in preoperatively nontreated
and PrOpChTh WTs (37.5% vs. 34.3%, respectively, p > 0.05, Fisher test).
In patients with PrOpChTh, tumors with cyclin A overexpression were larger
(10.5 ± 4.06 cm) than those with low cyclin A level (7.52 ± 5.57 cm), (p = 0.012, t-test).
Cyclin A overexpression was found more often in stages 3 and 4 (77.8%, 66.7%,
respectively) than in stages 1 and 2 (13.3% and 12.5%, respectively), (p = 0.004,
Pearson w2), (Table 1). Regarding histological type, cyclin A overexpression was found
most often in focal anaplasia, stromal, and diffuse anaplastic WTs (Table 2). No difference
was found between diffuse anaplastic and other histological types (p = 0.266, Fisher test).
In 8/25 (32%) cases of IR tumors and in 4/10 (40%) cases of HR tumors we detected
cyclin A overexpression, but without difference (p = 0.706, Fisher test), (Table 1).
A B
C D
Figure 1 Immunohistochemical staining of cyclin A in kidney tissue. (A) Normal tissue where cyclin
A shows focal nuclear and cytoplasmic staining in tubular epithelial cells (20). (B–D) Tumor where
cyclin A shows diffuse nuclear staining in: (B) epithelial component (40), (C) stromal component
(40) and (D) blastemal component (20). The IHC staining of normal lymph node tissue was used as a
positive control (the image is included in (A)). Full-size DOI: 10.7717/peerj.6212/ﬁg-1
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Cyclin A expression in individual components of WT
Epithelial and blastemal components of all WTs examined, overexpressed cyclin A with
similar frequency (31.3% and 37.1%, respectively; p = 0.797), and more often than
the stromal component (17.7%, p = 0.255 and p = 0.106, respectively; Fisher test),
(Table 2). Epithelial component was not present in three cases. Similar to analysis of all
components together, in epithelial component, we found no difference in cyclin A
overexpression in relation to PrOpChTh (p = 0.225), tumor size (p = 0.088), and
prognostic category (p = 1.000, Fisher test). Cyclin A overexpression was detected in
55.6% and 33.3% in stages 3 and 4, respectively and in 20% and 12.5% in stages 1 and 2,
respectively (p = 0.187) (Table 1). There was no difference in cyclin A overexpression
between diffuse anaplastic and other histological types (p = 0.224, Fisher test).
In blastemal component, the cyclin A overexpression was more frequent in stages 3 and 4
(77.8% and 66.7%, respectively) compared to stages 1and 2 (13.3% and 25%, respectively,
p = 0.009, Pearson w2), (Table 1), whereas there was no difference in relation to
PrOpChTh (p = 0.691), prognostic category (p = 0.444), and tumor size (p = 0.164,
Fisher test). Overexpression of cyclin A related to histological type showed no difference
between diffuse anaplastic and other histological types (p = 0.541, Fisher test), (Table 2).
The stromal component was not present in one sample. The cyclin A overexpression
(Table 1) revealed no difference in relation to stages 3 and 4 (22.2% and 66.7%,
respectively) and stages 1 and 2 (6.67% and 12.5%, respectively), (p = 0.085, Pearson w2).
There was no difference in relation to PrOpChTh (p = 0.635), tumor size (p = 0.148),
prognostic category (p = 1.000), and between diffuse anaplastic WT and other
histological types (p = 0.442), (Table 2).
Table 2 The frequency of cyclin A overexpression in different histological types of Wilms tumor (A)
patients who received preoperative therapy and (B) patients who did not receive preoperative
therapy.
Histological type Cyclin A overexpression (++/+++)
E B S T
A
Epithelial 1/2 (50%) 0/2 (0%) 0/1 (0%) 0/2 (0%)
Stromal 1/5 (20%) 3/5 (60%) 2/5 (40%) 3/5 (60%)
Mixed 2/7 (28.6%) 3/9 (33.3) 1/9 (11.1%) 3/9 (33.3%)
Regressive 2/7 (28.6%) 1/7 (14.3%) 1/7 (14.3%) 1/7 (14.3%)
Focal anaplasia 2/2 (100%) 2/2 (100%) 0/2 (0%) 2/2 (100%)
Blastemal 0/6 (0%) 2/7 (28.6%) 1/7 (0%) 1/7 (14.3%)
Diffuse anaplastic 2/3 (66.7%) 2/3 (66.7%) 1/3 (33.3%) 2/3 (66.7%)
B
Mixed 0/1 (0%) 1/1 (100%) 0/1 (0%) 0/1 (0%)
Blastemal 3/5 (60%) 2/5 (40%) 2/5 (40%) 2/5 (40%)
Diffuse anaplastic 1/1 (100%) 1/2 (50%) 0/2 (0%) 1/2 (50%)
Note:
E, epithelial component; B, blastemal component; S, stromal component; T, all components; ++/+++, positive staining in
10–50% of cells and in more than 50% of cells, respectively.
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Cyclin A expression in primary WT and WTs with metastasis
Cyclin A overexpression in all components was more frequent in WTs with metastasis
compared to WTs without metastasis (Table 1) but without difference (66.7% vs. 31.3%,
p = 0.265, Fisher test). There was also no signiﬁcant difference in frequency of
cyclin A overexpression in individual components between WTs with and WTs without
metastasis (Table 1). We did not detect cyclin A overexpression in only one case of primary
tumor with metastasis, which was regressive histological type.
Survival analysis
The OS analysis (Fig. 2A) revealed that 97.1%, 71.4%, and 60% of PrOpChTh patients and
75%, 50%, and 25% of patients without therapy were alive after 1, 3, and 5 years,
respectively (Log-rank 3.650, p = 0.056). The correlation was found for survival and stage
(Log-rank 21.640, p = 0.000), and prognostic group (Log-rank 11.263, p = 0.001),
(Figs. 2B–2C). After 5 years of follow-up, patients with stage 1 and 2 tumors had OS of 80%
and 62.5%, respectively, while patients with stage 3 and 4 had OS of 44.4% and 0%,
respectively. The rates of OS after 1, 3, and 5 years for patients with IR prognostic
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Figure 2 Overall survival of patients with Wilms tumor according to clinicopathological parameters. (A) Preoperative chemotherapy treatment
(PrOpChTh), (B) tumor stage, (C) prognostic group: intermediate risk (IR), high risk (HR), and (D) histological type (diffuse anaplastic vs. other
types of WT). Full-size DOI: 10.7717/peerj.6212/ﬁg-2
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Figure 3 Overall survival of patients with Wilms tumor stratiﬁed by cyclin A expression. (A) All components (total expression), (B) epithelial
component, (C) blastemal component, and (D) stromal component. No/focal–absence of staining and positive staining in less than 10% of cells,
respectively; overexpression–positive staining in 10–50% of cells and in more than 50% of cells, respectively.
Full-size DOI: 10.7717/peerj.6212/ﬁg-3
Table 3 Factors affecting overall survival in patients with Wilms tumor.
Variable Univariate analysis
Coefﬁcient b HR 95% CI p
Prognostic group
IR 1.0
HR 1.581 4.859 1.668–14.152 0.004
Stage
Stage 1 1.0
Stage 2 0.796 2.216 0.447–10.995 0.330
Stage 3 1.371 3.938 0.931–16.655 0.062
Stage 4 3.182 24.102 3.879–149.742 0.001
B (cyclin A expression)
No/focal 1.0
Overexpression 1.107 3.025 1.043–8.777 0.042
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group were 100%, 84%, and 76%, respectively; patients with HR had survival rates of 90%,
40%, and 20% after 1, 3, and 5 years. In the group of patients with diffuse anaplastic
WT, the OS was 0% after 3-year period in comparison to all other histological types
(Log-rank 8.759, p = 0.003), (Fig. 2D). There was no difference in OS between patients
related to gender (Log-rank 2.763, p = 0.096). In regard to OS and cyclin A expression,
there was no correlation in all WT components (total expression), (Log-rank 3.160,
p = 0.075), while in individual WT components the correlation was found only in
blastemal component (Log-rank 5.035, p = 0.025). Patients who overexpressed cyclin A
in blastemal component had the 5-year OS of 38.5%, (Figs. 3A–3D).
Univariate analysis (Table 3) showed that tumor stage (p = 0.001), prognostic group
(p = 0.004), as well as cyclin A expression in blastemal component (p = 0.042),
were signiﬁcant prognostic factors for OS. After multivariate analysis, none of these
factors remained statistically signiﬁcant.
DISCUSSION
The results of our study showed that cyclin A overexpression in WT was more
frequent in advanced stages and tumors with metastasis, which indicated that cyclin A
overexpression may be associated with tumor progression. Cyclins play a multifunctional
role in cancer pathogenesis and alterations in their structure and function can lead to
an array of cancer types (Stamatakos et al., 2010). Prognostic value of cyclins in WT was
also investigated previously (Radojevic-Skodric et al., 2007; Basta-Jovanovic et al., 2008).
Faussillon et al. (2005) reported increased expression of cyclin D2 in 86% of WT
cases. Berrebi et al. (2008) showed that cyclin E overexpression may have prognostic value
in WT. Similarly, Taran et al. (2011) observed higher values of cyclin E1 related to
WT cases with less favorable prognosis. However, to our knowledge, analysis of
cyclin A expression in WT has not been reported. Normal kidney tissue, analyzed in this
study, showed focal cyclin A expression. This ﬁnding conﬁrms that normal renal tissue
has a low proliferative capacity (Clapp & Cloker, 1997). In our study, about 34%
WT showed cyclin A overexpression, deﬁned as increased level of cyclin A comparing
with normal kidney tissue. Cyclin A overexpression was found in different human
tumors in adults (Aaltomaa et al., 1999; Poikonen et al., 2005; Sørby et al., 2012;
Cyniak-Magierska et al., 2015), as well as in pediatric embryonal tumors (Moschovi et al.,
2011) and in neuroblastoma tumor NI65 (Molenaar et al., 2003). In contrast, Wang
et al. (1996) reported decreased expression of cyclin A in colon cancer compared to
normal colon mucosa in 63% cases.
The overexpression of cyclin A has also been considered with reference to the sensitivity
for chemotherapy. Huuhtanen et al. (1999) reported association between higher cyclin A
score and good chemotherapy response in soft tissue sarcoma patients but no such
association was found in breast cancer patients (Poikonen et al., 2005). On the other hand,
cyclin A overexpression should also be considered in terms of chemotherapy resistance
(Cybulski et al., 2015; Huang et al., 2016). In our study, cyclin A overexpression
(total, epithelial, blastemal, and stromal component) was not found to be related with
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PrOpChTh treatment. Survival analysis showed the similar OS rate between untreated
patients and those treated with PrOpChTh.
We also investigated the association between cyclin A overexpression and the WT size.
Although tumors that showed cyclin A overexpression were larger, no difference
proved to be statistically signiﬁcant. In previous reports on different tumors, cyclin A
overexpression demonstrated good correlation with tumor grade (Handa et al., 1999;
Ito et al., 2002; Saarilahti et al., 2003; Sørby et al., 2012), but not with tumor size (Oda et al.,
2003; Ha et al., 2012). There have been no results regarding cyclin A or any other
cyclin expression in relation to size of WT published so far. The expression of cyclin A was
more frequent in stages 3 and 4 compared to stages 1 and 2. Other studies also showed
that cyclin A overexpression was signiﬁcantly linked to the advanced stages of
different tumors (Chen et al., 2003; Oda et al., 2003; Miao et al., 2015). Conversely,
there was no difference in cyclin A expression between different stages of colorectal
carcinoma (Handa et al., 1999), laryngeal cancer (Saarilahti et al., 2003), as well as
non-small lung cancers (Ha et al., 2012). The stage of WT is well known independent
prognostic factor, therefore this statistically signiﬁcant correlation between the WT stage
and cyclin A overexpression suggests that increased expression of cyclin A may be related
to the poor prognosis of WT. This is in accordance with our survival analysis. In our
cohort, in comparison to stage 1, patients with stages 3 and 4 had about 4 and 24 times
greater risk of dying, while those with stage 2 had the similar risk.
We found overexpressed cyclin A more often in epithelial and blastemal component
compared to stromal. The most investigated marker of proliferative activity of WT is
Ki-67, which is also far more often expressed in epithelial and blastemal than in stromal
component of WT (Juszkiewicz et al., 1997; Berrebi et al., 2008). The results of our and
these previous studies (Nagoshi & Tsuneyoshi, 1994) could be explained by WT
development theory (Beckwith, 1993; Beniers et al., 2001). Namely, normal differentiation
of blastemal component, which arises from metanephric blastema, is disrupted and
consequently immature tubules and abortive glomerules are formed, with the more
pronounced proliferative capacity. There was no signiﬁcant difference in cyclin A
expression between histological types of WT. However, overexpression of cyclin A
(total expression and expression in individual components of WT) was observed most
often in diffuse anaplastic and focal anaplasia. This result is in agreement with the
results of other studies, which showed correlation between overexpression of
cyclin A and poorly differentiated tumors (Handa et al., 1999; Ito et al., 2002;
Saarilahti et al., 2003).
Although histological features and stage of WT play the most important role in the
assessment of prognosis, there is a growing number of molecular biology markers that
possibly could allow identiﬁcation of tumors with worse (HR–WT) and better
(IR–WT) prognosis. In our study, we found cyclin A overexpression more often in HR
prognostic group (blastemal type of WT after receiving chemotherapy and WTs with
diffuse anaplasia) than in IR prognostic group, but the observed difference was not
signiﬁcant. This is mainly due to an absence of association of cyclin A overexpression with
blastemal type WT, while tumors with diffuse anaplasia showed a high frequency of
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elevated cyclin A expression. Blastemal type WT has been included in high-risk category
WT in the last SIOP revision of classiﬁcation of renal tumor of childhood (Vujanic et al.,
2002). We found no difference in cyclin A levels in blastemal WT regarding the
PrOpChTh usage. Although it is assumed that resistance to chemotherapy is a common
denominator, our results could suggest that WT with diffuse anaplasia, in addition,
have increased proliferation capacity. In our study, cyclin A overexpression was most often in
WT with focal and diffuse anaplasia, and recently it has been suggested that focal anaplasia
could have similar prognostic signiﬁcance as the diffuse (Sebire & Vujanic, 2009). The HR
prognostic group in our study had about ﬁve times greater risk of dying than the IR group
of patients. In our study, cyclin A overexpression was found more often in primary WT
tumors with metastasis compared to those without metastasis but without signiﬁcant
difference. Different results were obtained for cyclin E in WT. Berrebi et al. (2008) indicated
that cyclin E was correlated with tumor aggressiveness and metastases, and that assessment of
its expression may have prognostic value in the categorization of WT.
CONCLUSIONS
Our results do not conﬁrm prognostic signiﬁcance of cyclin A; however, this study showed
that cyclin A overexpression might be associated with the development and progression of
WT with anaplasia. Also, cyclin A overexpression was more frequently observed in
advanced stages (3 and 4) of WT, in the group of high-risk WTs, and in focal and diffuse
anaplasia WTs, which suggest that cyclin A overexpression may be associated with the
unfavorable prognosis. Based on our results there was no relation of cyclin A
overexpression and metastatic ability of WT. The larger cohort of patients would provide a
better evaluation of the association of cyclin A overexpression and unfavorable prognosis
in WT patients. The limitations of this study are a small number of patients and
retrospective design.
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